Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: Implications in immune privilege

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 89-100

  Rajashekhar, G ^a   Loganath, A ^a   Roy, A C ^a   Mongelli, J M ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Apoptosis; cFLIP; Cycloheximide; FasL; Immune privilege

Indexed keywords

CYCLOHEXIMIDE; FAS ANTIBODY; MONOCLONAL ANTIBODY;

ALLOGRAFT; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL LINE; CELL RESPIRATION; CELL VIABILITY; CHORIOCARCINOMA; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TROPHOBLAST;

EID: 0141645593     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00396-2     Document Type: Article

References (51)

1. Ashkenazi A., Dixit V.M. Death receptors signaling and modulation . Science. 281:1998;1309-1312.
2. Wang J., Lenardo M.J. Molecules involved in cell death and peripheral tolerance. Curr Opin Immunol. 9:1997;818-825.
3. Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 154:1995;3806-3813.
4. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
5. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
6. Koji T., Hishikawa Y., Ando H., Nakanishi Y., Kobayashi N. Expression of Fas and Fas ligand in normal and ischemia-reperfusion testes involvement of the Fas system in the induction of germ cell apoptosis in the damaged mouse testis . Biol Reprod. 64:2001;946-954.
7. Ferguson T.A., Green D.R. Fas-ligand and immune privilege the eyes have it . Cell Death Differ. 8:2001;771-772.
8. Lau H.T., Yu M., Fontana A., Stoeckert C.J. Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:1996;109-112.
9. Baldwin R.L., Tran H., Karlan B.Y. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol. 74:1999;265-271. doi:10.1006/gyno.1999.5448.
10. Gutierrez L.S., Eliza M., Niven-Fairchild T., Naftolin F., Mor G. The Fas/Fas-ligand system a mechanism for immune evasion in human breast carcinomas . Breast Cancer Res Treat. 54:1999;245-253.
11. O'Connell J., Bennett M.W., Nally K., Houston A., O'Sullivan G.C., Shanahan F. Altered mechanisms of apoptosis in colon cancer Fas resistance and counterattack in the tumor-immune conflict . Ann N Y Acad Sci. 910:2000;178-192.
12. Reimer T., Herrning C., Koczan D., Richter D., Gerber B., Kabelitz D., Friese K., Thiesen H.J. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res. 60:2000;822-828.
13. Ito Y., Monden M., Takeda T., Eguchi H., Umeshita K., Nagano H., Nakamori S., Dono K., Sakon M., Nakamura M., Tsujimoto M., Nakahara M., Nakao K., Yokosaki Y., Matsuura N. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer. 82:2000;1211-1217.
14. Mottolese M., Buglioni S., Bracalenti C., Cardarelli M.A., Ciabocco L., Giannarelli D., Botti C., Natali P.G., Concetti A., Venanzi F.M. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 89:2000;127-132.
15. Mundle S.D., Raza A. Defining the dynamics of self-assembled Fas-receptor activation. Trends Immunol. 23:2002;187-194.
16. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack cancer as a site of immune privilege . Immunol Today. 20:1999;46-52.
17. Patillo R.A., Gey G.O. The establishment of a cell line of human hormone-synthesizing trophoblast cells in vitro. Cancer Res. 28:1968;1231-1236.
18. Nozawa S., Udagawa Y., Sakayori M., Tsukazaki K., Takayama Y., Aoki D., Kubushiro K., Iizuka R., Inaba N. Establishment and characteristics of a new human choriocarcinoma cell line and its production of tumor markers. Nippon Sanka Fujinka Gakkai Zasshi. 39:1987;889-896.
19. Nagata S., Suda T. Fas and Fas ligand lpr and gld mutations . Immunol Today. 16:1995;39-43.
20. Rajashekhar G., Loganath A., Roy A.C., Wong Y.C. Expression and localization of angiogenin in placenta enhanced levels at term over first trimester villi . Mol Reprod Dev. 62:2002;97-101. doi:10.1002/mrd.10116.
21. L in colonic adenocarcinoma. J Pathol. 194:2001;15-19.
22. Balkundi D.R., Hanna N., Hileb M., Dougherty J., Sharma S. Labor-associated changes in Fas ligand expression and function in human placenta. Pediatr Res. 47:2000;301-308.
23. Anzar M., He L., Buhr M.M., Kroetsch T.G., Pauls K.P. Sperm apoptosis in fresh and cryopreserved bull semen detected by flow cytometry and its relationship with fertility. Biol Reprod. 66:2002;354-360.
24. Rajashekhar G, Loganath A, Roy AC, Mongelli JM. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines. Gynecol Oncol 2003;91:101-111.
25. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand implications for tumor immune escape . Science. 274:1996;1363-1366.
26. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism if immune evasion? Nature Med. 2:1996;1361-1366.
27. Payne S.G., Smith S.C., Davidge S.T., Baker P.N., Guilbert L.J. Death receptor Fas/Apo-1/CD95 expressed by human placental cytotrophoblasts does not mediate apoptosis. Biol Reprod. 60:1999;1144-1150.
28. Kim K.M., Lee K., Hong Y.S., Park H.Y. Fas-mediated apoptosis and expression of related genes in human malignant haematopoietic cells. Exp Mol Med. 32:2000;246-254.
29. Irisarri M., Plumas J., Bonnefoix T., Jacob M.C., Roucard C., Pasquier M.A., Sotto J.J., Lajmanovich A. Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia. 14:2000;2149-2158.
30. Kongphanich A., Hieda M., Kurokawa K., Murata T., Kobayashi N. Overcoming the blockade at the upstream of caspase cascade in Fas-resistant HTLV-I-infected T cells by cycloheximide. Biochem Biophys Res Commun. 294:(3):2002;714-718. Jun 14.
31. Shima Y., Nishimoto N., Ogata A., Fujii Y., Yoshizaki K., Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 85:1995;757-764.
32. Krueger A., Baumann S., Krammer P.H., Kirchhoff S. FLICE-inhibitory proteins regulators of death receptor-mediated apoptosis . Mol Cell Biol. 21:2001;8247-8254.
33. Budd R.C. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest. 109:2002;437-441.
34. Aschkenazi S., Straszewski S., Verwer K.M., Foellmer H., Rutherford T., Mor G. Differential regulation and function of the fas/fas ligand system in human trophoblast cells. Biol Reprod. 66:2002;1853-1861.
35. McMaster M.T., Bass K.E., Fisher S.J. Human trophoblast invasion. Autocrine control and paracrine modulation. Ann N Y Acad Sci. 734:1994;122-131.
36. Djerbi M., Screpanti V., Catrina A.I., Bogen B., Biberfeld P., Grandien A. The inhibitor of death receptor signaling. FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 190:1999;1025-1032.
37. Medema J.P., de Jong J., van Hall T., Melief C.J., Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Me. 190:1999;1033-1038.
38. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., Tschopp J. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk-signaling pathways. Curr Biol. 10:2000;640-648.
39. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
40. Yeh J.H., Hsu S.C., Han S.H., Lai M.Z. Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression. J Exp Med. 188:1998;1795-1802.
41. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nature Rev Mol Cell Biol. 2:2001;917-924.
42. Whiteside T.L. Induced-induced death of immune cells its mechanisms and consequences . Semin Cancer Biol. 12:2002;43-50.
43. Uckan D., Steele A., Cherry Wang B.Y., Wang B.Y., Chamizo W., Koutsonikolis A., Gilbert-Barness E., Good R.A. Trophoblasts express Fas ligand a proposed mechanism for immune privilege in placenta and maternal invasion . Mol Hum Reprod. 3:1997;655-662.
44. Kauma S.W., Huff T.F., Hayes N., Nilkaeo A. Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus. J Clin Endocrinol Metab. 84:1999;2188-2194.
45. Coumans B., Thellin O., Zorzi W., Melot F., Bougoussa M., Melen L., Zorzi D., Hennen G., Igout A., Heinen E. Lymphoid cell apoptosis induced by trophoblastic cells a model of active foeto-placental tolerance . J Immunol Methods. 224:1999;185-196.
46. Kniss D.A. Isolation and spontaneous immortalization of trophoblast-like ED (27) cell lines. Placenta. 23:2002;100-101. (Letter to the Editor).
47. Mor G., Gutierrez L.S., Eliza M., Kahyaoglu F., Arici A. Fas-fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol. 40:1998;89-94.
48. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol. 12:2002;309-315. doi:10.1016/S1044-579X(02)00017-2.
49. Que F.G., Phan V.A., Phan V.H., Celli A., Batts K., LaRusso N.F., Gores G.J. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology. 30:1999;1398-1404.
50. Matsui H., Suzuka K., Iitsuka Y., Seki K., Sekiya S. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol. 78:2000;28-31. doi:10.1006/gyno.2000.5813.
51. Frost P., Ng C.P., Belldegrun A., Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol. 180:1997;70-83.